Harald Hampel, an expert in neurodegenerative diseases, has been appointed head of global medical affairs at Eisai Inc to oversee the company’s Alzheimer’s disease and dementia research. Dr Hampel was the founding director of the Alzheimer Memorial Center at the University of Munich in 1997 and most recently, professor and scientific director at the European Center of Excellence in Neurodegenerative Disease at Sorbonne University in Paris.
Separately, Eisai has promoted Michael Irizarry to head clinical development of the company’s Alzheimer’s-related neurosciences portfolio. Dr Irizarry formerly worked at Eli Lilly and Co and GlaxoSmithKline Plc.
Eisai announced the appointments on 2 May 2019.
Copyright 2019 Evernow Publishing Ltd.